News - Page 34 of 35 - MaRS Innovation

MaRS Innovation welcomes Thunder Bay Regional Research Institute as newest member

Dr. John Rowlands’ X-ray Light Valve technology among the first TBRRI patents that MaRS Innovation will bring to market January 26, 2011 (Thunder Bay, ON) – Today, MaRS Innovation welcomes Thunder Bay Regional Research Institute (TBRRI) as its newest member. MaRS Innovation is an incorporated non-profit organization with an international, independent, industry-led Board of Directors. It is the commercialization agent for 16 member institutions that are leading Ontario life sciences and commercialization agents. Partners include the University of Toronto, Sunnybrook Health Sciences Centre, ... Read more

VitalHub featured on CBC’s Metro Morning

Matt Galloway, host of CBC's Metro Morning, spoke to Prateek Dwivedi, vice-president and chief information officer at Mount Sinai Hospital, about VitalHub's technology. Dwivedi's interview with Galloway is no longer publicly available. Dwivedi and Galloway touch on various product highlights, including: Longitudinal view of a patient's history and benefits of having access to that information when making rounds or walking between locations. Security concerns, including encryption, that are equivalent to those used in the hospital. Feedback from doctors, nurses and others who have used the product. MaRS ... Read more

How VitalHub Corp. Uses iPhones® To Help Health Care

TORONTO, ON (Jan. 25, 2011) —Doctors, nurses and administrators can now access electronic health applications on mobile, hand-held technology through VitalHub Corp.. The unique start-up company was spun-off from mobile health technologies developed  Toronto's Mount Sinai Hospital, thanks in part to $300,000 in seed financing from MaRS Innovation that will give it a crucial head start in the fiercely competitive mobile IT health sector. MaRS Innovation invests in the most commercially promising discoveries emerging from its member institutions, which include 16 of Toronto's ... Read more

$15M Funding announcement for CCRM

As part of MaRS Innovation's strategy to bundle technologies, our first initiative focused on regenerative medicine and creating the Centre for Commercialization of Regenerative Medicine (CCRM) located in Toronto, Ontario. We are pleased that these efforts have been recognized by the Government of Canada's National Centres of Excellence (NCE) program, which recently announced a $15 million funding grant for CCRM through the Centres of Excellence for Commercialization and Research. (more…) Read more

Wound Healing Technology Exclusive Rights Deal with Cardium Therapeutics

TORONTO
 (October
 14,
 2010)
 –
 Of
 the
 approximately
 300
 million
 people
 around
 the
 world
 who
 are
 diabetics,
 45
 million
 of
 them
 develop 
foot
 ulcers 
that 
bleed
 – 
and 
the 
infection
 from
 those 
ulcers
 can 
spread. Working
 to
 halt
 this
 is
 Dr.
 Ping
 Lee,
 a
 professor
 at
 the
 University
 of
 Toronto’s (U of T)
 Leslie
 Dan
 Faculty
 of
 Pharmacy
 and
 GlaxoSmithKline
 chair
 in
 Pharmaceutics
 and 
Drug 
Delivery.
 He 
and 
his
 team
 have 
created 
a 
new 
sustained‐release
 form
 of
 nitric 
oxide 
(NO) 
that
 can
 not
 ... Read more

Xagenic secures $1 million investment in chip-based technology for detecting disease, cancer and infection

Funds secured from MaRS Innovation, HTX, OICR and CCR to speed commercialization of Xagenic's rapid molecular diagnostic technology TORONTO (October 13, 2010) – MaRS Innovation today announced a $500,000 investment in its Toronto-based spin-off company, Xagenic Inc. When combined with funds from other investors and lenders, the new working capital provided to Xagenic totals $1.04 million. This follow‐on financing includes a $300,000 loan from HTX, The Health Technology Exchange; $200,000 from the Ontario Institute for Cancer Research; $40,000 from the Ontario Centre of Excellence ... Read more

Federal and Provincial Proof of Principle Programs Support Translational Technology Development

TORONTO (August 16, 2010) – MaRS Innovation (MI) is pleased to announce that translational funding to support product development for early-stage technologies from its members has been successfully deployed from federal and provincial sources. At the federal level, three of MI’s commercialization projects have recently received notification of funding from the Canadian Institutes of Health Research (CIHR) Proof of Principle (PoP) program, amounting to approximately $470,000. Moreover, MI has successfully deployed about $1 million in proof of principle funding received from the Ontario Ministry of Research ... Read more

MaRS Innovation establishes co-managed fund with Johnson & Johnson

MaRS Innovation (MI) has signed a co-funding agreement with the Johnson & Johnson Corporate Office of Science and Technology to capitalize and accelerate the use of Toronto-based life sciences technologies during the early stages of pharmaceutical and medical device development. The Translational Innovation Partnership Program (TIPP) is the first co-funding agreement of its kind for MI. (more…) Read more

MaRS Innovation and Sunnybrook Health Sciences Centre Partner to Develop Four Exciting Medical Discoveries

TORONTO (March 23, 2010) — MaRS Innovation and Sunnybrook Health Sciences Centre have entered into their first set of agreements to collaboratively commercialize a novel therapeutic technology and three advances in medical imaging. These four technologies will impact diagnosis and care for epidemic chronic illnesses and have clear and broad commercial potential. MI will shepherd these opportunities through the next stages of the commercialization process. “We are coming out of the gate vigorously in identifying this group of Sunnybrook technologies as commercialization ... Read more

CIHR Commercialization Program funds insulin-alternative stem cell technology and nicotine addiction drug therapy

TORONTO (March 2, 2010) – MaRS Innovation is delighted to announce that two of its commercialization projects – notably an umbilical cord stem cell technology from Mount Sinai Hospital and nicotine addiction therapy from the Centre for Addiction and Mental Health (CAMH) - have received Canadian Institutes of Health Research (CIHR) Proof of Principle (PoP) funding. This funding – each grant is valued at $150,000 – is third party validation of MaRS Innovation’s approach to commercializing its members’ discoveries. The CIHR performs rigorous due diligence and ... Read more
Page 34 of 35« First...1020...3132333435